Cardiac biomarkers alterations in patients with SARS-CoV-2 infection

1. KURZ DJ, EBERLI FR. Cardiovascular aspects of COVID-19. Swiss Med Wkly. 2020;150:w20417.10.4414/smw.2020.2041733382450Search in Google Scholar

2. BHALLA V, BLISH CA, SOUTH AM. A historical perspective on ACE2 in the COVID-19 era [published online ahead of print, 2020 Dec 14]. J Hum Hypertens. 2020;1–5.10.1038/s41371-020-00459-3773539633318644Search in Google Scholar

3. BADER F, MANLA Y, ATALLAH B, STARLING RC. Heart failure and COVID-19. Heart Fail Rev. 2021;26(1):1–10.10.1007/s10741-020-10008-2738312232720082Search in Google Scholar

4. IMAZIO M, KLINGEL K, KINDERMANN I, BRUCATO A, DE ROSA FG, ADLER Y, et al. COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?. Heart. 2020;106(15):1127–1131.10.1136/heartjnl-2020-31718632499236Search in Google Scholar

5. LI L, ZHOU Q, XU J. Changes of Laboratory Cardiac Markers and Mechanisms of Cardiac Injury in Coronavirus Disease 2019. Biomed Res Int. 2020;2020:7413673.10.1155/2020/7413673725407832596365Search in Google Scholar

6. ABOUGHDIR M, KIRWIN T, ABDUL KHADER A, WANG B. Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review. Viruses. 2020;12(5):527.10.3390/v12050527729083832403242Search in Google Scholar

7. SHI X, CHEN M, ZHANG Y. The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. Mol Biol Rep. 2021;48(2):1763–1771.10.1007/s11033-021-06148-9782239833483864Search in Google Scholar

8. WU L, O’KANE AM, PENG H, BI Y, MOTRIUK-SMITH D, REN J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochem Pharmacol. 2020;178:114114.10.1016/j.bcp.2020.114114730610632579957Search in Google Scholar

9. ADEGHATE EA, EID N, SINGH J. Mechanisms of COVID-19-induced heart failure: a short review. Heart Fail Rev. 2021;26(2):363–369.10.1007/s10741-020-10037-x766697233191474Search in Google Scholar

10. COSTA IBSDS, BITTAR CS, RIZK SI, ARAÚJO FILHO AE, SANTOS KAQ, MACHADO TIV, et al. The Heart and COVID-19: What Cardiologists Need to Know. O Coração e a COVID-19: O que o Cardiologista Precisa Saber. Arq Bras Cardiol. 2020;114(5):805–816.10.36660/abc.20200279838699232401847Search in Google Scholar

11. HUANG C, WANG Y, LI X, REN L, ZHAO J, HU Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.10.1016/S0140-6736(20)30183-5Search in Google Scholar

12. MALIK P, PATEL U, PATEL NH, SOMI S, SINGH J. Elevated cardiac troponin I as a predictor of outcomes in COVID-19 hospitalizations: a meta-analysis. Infez Med. 2020;28(4):500–506.Search in Google Scholar

13. BAGATE F, MASI P, D’HUMIÈRES T, AL-ASSAAD L, CHAKRA LA, RAZAZI K, et al. Advanced echocardiographic phenotyping of critically ill patients with coronavirus-19 sepsis: a prospective cohort study. J Intensive Care. 2021;9(1):12.10.1186/s40560-020-00516-6781613633472693Search in Google Scholar

14. LI X, PAN X, LI Y, AN N, XING Y, YANG F, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020;24(1):468.10.1186/s13054-020-03183-z738617032723362Search in Google Scholar

15. GIUSTINO G, CROFT LB, STEFANINI GG, BRAGATO R, SILBIGER JJ, VICENZI M, et al. Characterization of Myocardial Injury in Patients With COVID-19. J Am Coll Cardiol. 2020;76(18):2043–2055.10.1016/j.jacc.2020.08.069758817933121710Search in Google Scholar

16. PEIRÓ ÓM, CARRASQUER A, SÁNCHEZ-GIMENEZ R, LAL-TREHAN N, DEL-MORAL-RONDA V, BONET G, et al. Biomarkers and short-term prognosis in COVID-19. Biomarkers. 2021;26(2):119–126.10.1080/1354750X.2021.1874052783245233426934Search in Google Scholar

17. SHOAR S, HOSSEINI F, NADERAN M, MEHTA JL. Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients With COVID-19. Am J Cardiol. 2020;135:50–61.10.1016/j.amjcard.2020.08.044747763732916148Search in Google Scholar

18. LI J, ZHANG Y, WANG F, LIU B, LI H, TANG Z, et al. Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19). BMC Cardiovasc Disord. 2020;20(1):479.10.1186/s12872-020-01758-w765257733167876Search in Google Scholar

19. MU S, WEI W, JIN C, PU N, YU K, GU G, et al. Risk factors for COVID-19 patients with cardiac injury: pulmonary ventilation dysfunction and oxygen inhalation insufficiency are not the direct causes. Aging (Albany NY). 2020;12(23):23464–23477.10.18632/aging.104148776251233226958Search in Google Scholar

20. SHAH P, DOSHI R, CHENNA A, OWENS R, COBB A, IVEY H, et al. Prognostic Value of Elevated Cardiac Troponin I in Hospitalized Covid-19 Patients. Am J Cardiol. 2020;135:150–153.10.1016/j.amjcard.2020.08.041745283532861733Search in Google Scholar

21. ÖZYILMAZ S, ERGÜN ALIŞ E, ERMIŞ E, ALLAHVERDIYEV S, UÇAR H. Assessment of the Relationship between Mortality and Troponin I Levels in Hospitalized Patients with the Novel Coronavirus (COVID-19). Medicina (Kaunas). 2020;56(12):693.10.3390/medicina56120693776316433322097Search in Google Scholar

22. MEDETALIBEYOGLU A, EMET S, SENKAL N, AYDOGAN M, KOSE M, TUKEK T. Cardiovascular view of intermediate and high-risk COVID-19 patients: single-centre experience with low mortality and intensive care hospitalisation rates. Cardiovasc J Afr. 2021;32(2):79–86.Search in Google Scholar

23. ARCARI L, LUCIANI M, CACCIOTTI L, MUSUMECI MB, SPUNTARELLI V, PISTELLA E, et al. Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. Intern Emerg Med. 2020;15(8):1467–1476.10.1007/s11739-020-02498-7752038032986136Search in Google Scholar

24. STEFANINI GG, CHIARITO M, FERRANTE G, CANNATA F, AZZOLINI E, VIGGIANI G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106(19):1512–1518.10.1136/heartjnl-2020-31732232817312Search in Google Scholar

25. QIN JJ, CHENG X, ZHOU F, LEI F, AKOLKAR G, CAI J, et al. Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. Hypertension. 2020;76(4):1104–1112.10.1161/HYPERTENSIONAHA.120.15528737517932673499Search in Google Scholar

26. SALVATICI M, BARBIERI B, CIOFFI SMG, MORENGHI E, LEONE FP, MAURA F, et al. Association between cardiac troponin I and mortality in patients with COVID-19. Biomarkers. 2020;25(8):634–640.10.1080/1354750X.2020.1831609771172833003961Search in Google Scholar

27. CAO J, ZHENG Y, LUO Z, MEI Z, YAO Y, LIU Z, et al. Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease. Theranostics. 2020;10(21):9663–9673.10.7150/thno.47980744991332863952Search in Google Scholar

28. HODGES G, PALLISGAARD J, SCHJERNING OLSEN AM, MCGETTIGAN P, ANDERSEN M, KROGAGER M, et al. Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study. BMJ Open. 2020;10(12):e041295.10.1136/bmjopen-2020-041295771292933268425Search in Google Scholar

29. RAAD M, DABBAGH M, GORGIS S, YAN J, CHEHAB O, DAGHER C, et al. Cardiac Injury Patterns and Inpatient Outcomes Among Patients Admitted With COVID-19. Am J Cardiol. 2020;133:154–161.10.1016/j.amjcard.2020.07.040737852332829913Search in Google Scholar

30. TORAIH EA, ELSHAZLI RM, HUSSEIN MH, ELGAML A, AMIN M, EL-MOWAFY M, et al. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis. J Med Virol. 2020;92(11):2473–2488.10.1002/jmv.26166730712432530509Search in Google Scholar

31. HE X, WANG L, WANG H, XIE Y, YU Y, SUN J, et al. Factors associated with acute cardiac injury and their effects on mortality in patients with COVID-19. Sci Rep. 2020;10(1):20452.10.1038/s41598-020-77172-1768636133235220Search in Google Scholar

32. YAO Q, NI J, HU TT, CAI ZL, ZHAO JH, XIE QW, et al. Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study. Rev Cardiovasc Med. 2020;21(4):615–625.10.31083/j.rcm.2020.04.11333388007Search in Google Scholar

33. ALOISIO E, CHIBIREVA M, SERAFINI L, PASQUALETTI S, FALVELLA FS, DOLCI A, et al. A Comprehensive Appraisal of Laboratory Biochemistry Tests as Major Predictors of COVID-19 Severity. Arch Pathol Lab Med. 2020;144(12):1457–1464.10.5858/arpa.2020-0389-SA32649222Search in Google Scholar

34. SINGH N, ANCHAN RK, BESSER SA, BELKIN MN, CRUZ MD, LEE L, et al. High sensitivity Troponin-T for prediction of adverse events in patients with COVID-19. Biomarkers. 2020;25(8):626–633.10.1080/1354750X.2020.1829056771174232981387Search in Google Scholar

35. LI C, JIANG J, WANG F, ZHOU N, VERONESE G, MOSLEHI JJ, et al. Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients. J Mol Cell Cardiol. 2020;147:74–87.10.1016/j.yjmcc.2020.08.008743827232827510Search in Google Scholar

36. POTERUCHA TJ, ELIAS P, JAIN SS, SAYER G, REDFORS B, BURKHOFF D, et al. Admission Cardiac Diagnostic Testing with Electrocardiography and Troponin Measurement Prognosticates Increased 30-Day Mortality in COVID-19. J Am Heart Assoc. 2021;10(1):e018476.10.1161/JAHA.120.018476795550233169643Search in Google Scholar

37. SI D, DU B, NI L, YANG B, SUN H, JIANG N, et al. Death, discharge and arrhythmias among patients with COVID-19 and cardiac injury. CMAJ. 2020;192(28):E791–E798.10.1503/cmaj.200879782886532586839Search in Google Scholar

38. ZHOU M, WONG CK, UN KC, LAU YM, LEE JC, TAM FC et al. Cardiovascular sequalae in uncomplicated COVID-19 survivors. PLoS One. 2021;16(2):e0246732.10.1371/journal.pone.0246732787758833571321Search in Google Scholar

39. GHIO S, BALDI E, VICENTINI A, LENTI MV, DI SABATINO A, DI MATTEO A, et al. Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. Intern Emerg Med. 2020;15(8):1457–1465.10.1007/s11739-020-02493-y750594232960429Search in Google Scholar

40. LI J, GUO T, DONG D, ZHANG X, CHEN X, FENG Y, et al. Defining heart disease risk for death in COVID-19 infection. QJM. 2020;113(12):876–882.10.1093/qjmed/hcaa246745491332790836Search in Google Scholar

41. BELARTE-TORNERO LC, VALDIVIELSO-MORÉ S, VICENTE ELCANO M, SOLÉ-GONZÁLEZ E, RUÍZ-BUSTILLO S, CALVO-FERNÁNDEZ A, et al. Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection. J Clin Med. 2021;10(2):323.10.3390/jcm10020323782989933477268Search in Google Scholar

42. ZYLLA MM, MERLE U, VEY JA, KOROSOGLOU G, HOFMANN E, MÜLLER M, et al. Predictors and Prognostic Implications of Cardiac Arrhythmias in Patients Hospitalized for COVID-19. J Clin Med. 2021;10(1):133.10.3390/jcm10010133779604133401735Search in Google Scholar

43. MANOCHA KK, KIRZNER J, YING X, YEO I, PELTZER B, ANG B, et al. Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID-19: Derivation and Validation of the HA2T2 COVID-19 Mortality Risk Score. J Am Heart Assoc. 2021;10(6):e018477.10.1161/JAHA.120.018477817419033121304Search in Google Scholar

44. MAHMOUD-ELSAYED HM, MOODY WE, BRADLOW WM, KHAN-KHEIL AM, SENIOR J, HUDSMITH LE, et al. Echocardiographic Findings in Patients With COVID-19 Pneumonia. Can J Cardiol. 2020;36(8):1203–1207.10.1016/j.cjca.2020.05.030725573432474111Search in Google Scholar

45. CHEN LQ, BURDOWSKI J, MARFATIA R, WEBER J, GLIGANIC K, DIAZ N, et al. Reduced cardiac function is associated with cardiac injury and mortality risk in hospitalized COVID-19 Patients. Clin Cardiol. 2020;43(12):1547–1554.10.1002/clc.23479767537133280140Search in Google Scholar

46. VAN DEN HEUVEL FMA, VOS JL, KOOP Y, VAN DIJK APJ, DUIJNHOUWER AL, DE MAST Q, et al. Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19. Neth Heart J. 2020;28(7-8):410–417.10.1007/s12471-020-01458-2734147132643071Search in Google Scholar

47. LAZZERI C, BONIZZOLI M, BATACCHI S, CIANCHI G, FRANCI A, FULCERI GE, et al. Cardiac Involvment in COVID-19-Related Acute Respiratory Distress Syndrome. Am J Cardiol. 2020;132:147–149.10.1016/j.amjcard.2020.07.010735532532762961Search in Google Scholar

48. GHIO S, BALDI E, VICENTINI A, LENTI MV, DI SABATINO A, DI MATTEO A, et al. Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. Intern Emerg Med. 2020;15(8):1457–1465.10.1007/s11739-020-02493-y750594232960429Search in Google Scholar

49. SONSOZ MR, ONCUL A, CEVIK E, ORTA H, YILMAZ M, AYDUK GOVDELI E, et al. Wide QRS Complex and Lateral ST-T Segment Abnormality Are Associated With Worse Clinical Outcomes in COVID-19 Patients. Am J Med Sci. 2021;361(5):591–597.10.1016/j.amjms.2020.12.012783445733581838Search in Google Scholar

50. SANGHVI SK, SCHWARZMAN LS, NAZIR NT. Cardiac MRI and Myocardial Injury in COVID-19: Diagnosis, Risk Stratification and Prognosis. Diagnostics (Basel). 2021;11(1):130.10.3390/diagnostics11010130783088933467705Search in Google Scholar

51. KNIGHT DS, KOTECHA T, RAZVI Y, CHACKO L, BROWN JT, JEETLEY PS, et al. COVID-19: Myocardial Injury in Survivors. Circulation. 2020;142(11):1120–1122.10.1161/CIRCULATIONAHA.120.049252749239632673505Search in Google Scholar

52. LAI CC, SUNG MI, HO CH, LIU HH, CHEN CM, CHIANG SR, et al. The prognostic value of N-terminal proB-type natriuretic peptide in patients with acute respiratory distress syndrome. Sci Rep. 2017;7:44784.10.1038/srep44784535960828322314Search in Google Scholar

53. UELAND T, HEGGELUND L, LIND A, HOLTEN AR, TONBY K, MICHELSEN AE, et al. Elevated plasma sTIM-3 levels in patients with severe COVID-19. J Allergy Clin Immunol. 2021;147(1):92–98.10.1016/j.jaci.2020.09.007750313532971109Search in Google Scholar

54. BANSAL A, KUMAR A, PATEL D, PURI R, KALRA A, KAPADIA SR, et al. Meta-analysis Comparing Outcomes in Patients With and Without Cardiac Injury and Coronavirus Disease 2019 (COVID 19). Am J Cardiol. 2021;141:140–146.10.1016/j.amjcard.2020.11.009767193433217345Search in Google Scholar

55. PRANATA R, HUANG I, LUKITO AA, RAHARJO SB. Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Postgrad Med J. 2020;96(1137):387–391.10.1136/postgradmedj-2020-137884731612132434874Search in Google Scholar

56. GAO L, JIANG D, WEN XS, CHENG XC, SUN M, HE B, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):83.10.1186/s12931-020-01352-w715689832293449Search in Google Scholar

57. ABDEEN Y, KAAKO A, ALNABULSI M, OKEH A, MENG W, MILLER R. The prognostic effect of brain natriuretic peptide levels on outcomes of hospitalized patients with COVID-19. Avicenna J Med. 2021;11(1):20–26.10.4103/ajm.ajm_169_20783926433520785Search in Google Scholar

58. ALMEIDA JUNIOR GLG, BRAGA F, JORGE JK, NOBRE GF, KALICHSZTEIN M, FARIA PMP, et al. Prognostic Value of Troponin-T and B-Type Natriuretic Peptide in Patients Hospitalized for COVID-19. Valor Prognóstico da Troponina T e do Peptídeo Natriurético Tipo B em Pacientes Internados por COVID-19. Arq Bras Cardiol. 2020;115(4):660–666.10.36660/abc.20200385838696433111866Search in Google Scholar

59. MYHRE PL, PREBENSEN C, STRAND H, RØYSLAND R, JONASSEN CM, RANGBERG A, et al. Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19. Circulation. 2020;142(22):2128–213710.1161/CIRCULATIONAHA.120.050360768808433058695Search in Google Scholar